Related Experiment Video

Updated: Aug 15, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Combination therapy for multiple sclerosis

R E Gonsette1

  • 1National Centre for MS, B 1820 Melsbroek, Belgium.

International MS Journal
|May 6, 2004
PubMed

Insights

Combination therapy for multiple sclerosis (MS) aims to enhance treatment benefits and manage relapses. Safety studies are crucial before testing efficacy against current monotherapies.

Area of Science:

  • Neuroimmunology
  • Pharmacology
  • Clinical Neurology

Background:

  • Multiple sclerosis (MS) treatments aim to target inflammatory, oxidative, and excitotoxic pathways.
  • Over 25 combination therapies have been explored to improve outcomes beyond monotherapy.
  • Current combination therapies are investigated as fixed-dose or sequential regimens.

Purpose of the Study:

  • To evaluate the potential of combination therapies to improve benefits and tolerance in MS patients.
  • To explore strategies for managing relapses and disease progression in non-responsive patients.
  • To assess the safety and efficacy of combining MS treatments.

Main Methods:

  • Review of recent clinical trials on combination therapies in multiple sclerosis.
  • Analysis of therapeutic targets common to both monotherapy and combination therapy.
  • Consideration of safety and efficacy study designs for combination treatments.

Main Results:

  • Preliminary data suggest combination therapies may not increase side-effects compared to monotherapy.
  • Combination therapy offers potential benefits for patients with partial responses or non-response to current treatments.
  • Further investigation is needed to establish efficacy over monotherapy.

Conclusions:

  • Combination therapy is a promising strategy to enhance multiple sclerosis (MS) treatment.
  • Prioritizing safety studies is essential before conducting large-scale efficacy trials.
  • Combination treatments warrant further investigation to optimize MS management.

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...